Alexion to Start Pivotal Study on Ultomiris for ALS in Q1

Alexion Pharmaceuticals Inc. ALXN announced plans to start a pivotal phase III study to evaluate its long-acting C5 complement inhibitor, Ultomiris (ravulizumab), in a new indication — amyotrophic lateral sclerosis (ALS).